Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B-Virus-Marker und Rötelnantikörper bei Patienten mit Hodgkin-, Non-Hodgkin-Lymphomen und allgemein internistischen Erkrankungen

Frequency of hepatitis B virus markers and antibodies to rubella viruses in patients with lymphoproliferative disorders

  • Originalarbeiten
  • Published:
Blut Aims and scope Submit manuscript

Summary

Sera of 108 patients with malignant lymphomas (47 Hodgkin and 61 non-Hodgkin's lymphomas) and sera of 108 consecutive patients from a general medical ward as a control group were tested for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and antibodies to hepatitis B virus (HBV) by solid phase radioimmunoassay. Ninety-six of the lymphoma sera and 89 of the control group sera were also tested for antibodies to rubella viruses (RV) by hemagglutination inhibition. HBsAg was present in 2 (1.9%) of the 108 lymphoma sera and 4 (3.7%) of the 108 control group sera. HBeAg was found in one of the lymphoma and in two of the control cases. Twenty-three (21%) of the patients with lymphoproliferative disorders and 28 (26%) of the control group had antibodies to HBV. The percentage of patients without antibodies to RV was significantly lower in the control group (15/89= 17%) and in the group with Hodgkin's disease (7/44 = 16%) than in the non-Hodgkin's lymphoma group (19/52=37%; p < 0.01; p < 0.05). The present study shows that the prevalence of HBV serologic markers in patients with lymphoproliferative disorders is low compared to previous reports, although antiviral immunity, as measured by anti-RV titers, was impaired in the non-Hodgkin's lymphoma group. Probably due to the routine HBsAg screening of blood and blood products given to oncologic patients in our hospital the potential risk of the patients transmitting HBV is not higher than in a control group of a general medical ward.

Zusammenfassung

Seren von 108 nicht ausgesuchten Patienten mit malignen Lymphomen (47 Hodgkin- und 61 Non-Hodgkin-Lymphome) und Seren von 108 aufeinanderfolgenden allgemein internistischen Patienten wurden mittels Festphasenradioimmuntesten auf das Vorkommen von Hepatitis B-Oberflächenantigen (HBsAg), Hepatitis B-e-Antigen (HBeAg) und Hepatitis B Virus (HBV)-Antikörper untersucht. Gleichzeitig wurden bei 96 der Lymphom- und 89 der allgemein internistischen Patientenseren die Rötelnantikörper im Hämagglutinationshemmtest bestimmt. Zwei (1,9%) der Lymphom- und 4 (3,7%) der allgemein internistischen Patienten waren HBsAg-positiv, einmal bzw. zweimal mit gleichzeitigem Nachweis von HBeAg. Dreiundzwanzig (21%) der Patienten mit lymphoproliferativen Erkrankungen und 28 (26%) der allgemein internistischen Patienten wiesen einen oder mehrere HBV-Antikörper im Serum ohne gleichzeitige HBs-Antigenämie auf. Die Unterschiede sind statistisch nicht signifikant. Der Prozentsatz der Patienten ohne Rötelnantikörper (Titer < 1∶ 8) war bei den allgemein internistischen Patienten mit 17% (15 v. 89) und bei den Hodgkin-Patienten mit 16% (7 v. 44) signifikant niedriger (p < 0,01; p < 0,05) als bei den Non-Hodgkin-Lymphomen mit 19 v. 52 (37%). Lymphompatienten ohne immunsuppressive Therapie hatten signifikant häufiger Rötelnantikörper (über 1 ∶ 32) als die Patienten unter Zytostatika- oder Radiotherapie (p < 0,05). Ein Unterschied in der Prävalenz von HBV-Antikörpern bei Patienten mit und ohne immunsuppressive Behandlung (14% vs. 28%) war vorhanden, jedoch statistisch nicht signifikant. Eine Korrelation zwischen der Häufigkeit des HBV-Antikörper-Nachweises und der Rötelnantikörpertiterhöhe bei den Lymphompatienten bestand nicht.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Abt AB, Kirschner RH, Belliveau RE, O'Connell MJ, Sklansky BD, Greene WH, Wiernik PH (1974) Hepatic pathology associated with Hodgkin's disease. Cancer 33: 1564–1571

    PubMed  Google Scholar 

  2. Aisenberg AC (1966) Immunologic status of Hodgkin's disease. Cancer 19: 385–394

    Google Scholar 

  3. Berg PA (1976) Immunologie der Virushepatitis und ihre Folgezustände. Verh Dtsch Ges Inn Med 82: 74–87

    PubMed  Google Scholar 

  4. Cowan DH, Kouroupis GM, Leers WD (1975) Occurrence of hepatitis and hepatitis B surface antigen in adult patients with acute leukemia. Can Med Assoc J 112: 693–697

    PubMed  Google Scholar 

  5. Frösner GG, Sugg U, Haas H, Overby RL, Deinhardt F (1978) Solid phase radioimmunoassay for HBeAg and anti-HBe. Fresenius Z Anal Chem 290: 185

    Google Scholar 

  6. Grange MJ, Erlinger S, Teillet F, Schlegel N, Barge J, Degott C (1973) A possible relationship to treatment between hepatitis-associated antigen and chronic persistent hepatitis in Hodgkin's disease. Gut 14: 433–437

    PubMed  Google Scholar 

  7. Hansen MM (1973) Chronic lymphocytic leukaemia. Scand J Haematol [Suppl] 18: 89–92

    Google Scholar 

  8. Heimann R, Ray MB, Desmet V (1976) HBsAg, chronic lymphatic leukemia and cirrhosis. 10. International Congress of Gastroenterology, June 23–29, Budapest 1976, Abstract 635

  9. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ (1978) Type B Hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N EngI J Med 298: 1379–1383

    Google Scholar 

  10. Horstmann DM (1976) Rubella. In: Viral infections of humans. Evans AS (Hrsg). John Wiley & Sons Ltd, London New York Sydney Toronto, pp 409–427

    Google Scholar 

  11. Jones JV, Peacock DB, Greenham LW, Bullimore JA (1976) Antibody production in preclinical Hodgkin's disease. Lancet I: 92–93

    Google Scholar 

  12. Langenhuysen MM AC, Cazemier T, Houwen B, Brouwers ThM, Halie MR, The TH, Nieweg HO (1974) Antibodies to Epstein-Barr Virus, Cytomegalovirus, and Australia-antigen in Hodgkin's disease. Cancer 34: 262–267

    PubMed  Google Scholar 

  13. Lennert K, Mohri N (1974) Histologische Klassifizierung und Vorkommen des M. Hodgkin. Internist 15: 57–65

    PubMed  Google Scholar 

  14. Lennert K, Stein H, Kaiserling E (1975) Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer [Suppl. II] 31: 29–43

    Google Scholar 

  15. Levy R, Kaplan HS (1974) Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med 290: 181–186

    PubMed  Google Scholar 

  16. Linnemann CC, Hegg ME, Ramundo N, Schiff GM (1977) Screening hospital patients for hepatitis B surface antigen. Am J Clin Pathol 67: 257–259

    PubMed  Google Scholar 

  17. Lukes RJ, Craver LF, Hall TC, Rappaport H, Ruben P (1966) Report of the nomenclature committee. Cancer Res 26: 1311

    Google Scholar 

  18. Millian SJ, Miller DG, Schaeffer M (1965) Viral complement-fixing antibody in patients with Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma, and chronic lymphatic leukemia. Cancer 18: 674–678

    PubMed  Google Scholar 

  19. Nagington J, Cossart YE, Cohen BJ (1977) Reactivation of hepatitis B after transplantation operations. Lancet I: 558–560

    Google Scholar 

  20. Rocchi G, Tosato G, Papa G, Ragona G (1975) Antibodies to Epstein-Barr virus-associated nuclear antigen and to other viral and non-viral antigens in Hodgkin's disease. Int J. Cancer 16: 323–328

    PubMed  Google Scholar 

  21. Sauerbruch T, Frösner GG, Theml H, Kaess H (1979) Häufigkeit serologischer Hepatitis B Marker bei Patienten mit hämatologischen Erkrankungen im Vergleich zu Patienten einer allgemein internistischen Station und Blutspendern. Verh Dtsch Ges Inn Med 85: 560–563

    Google Scholar 

  22. Spero JA, Lewis JH, van Thiel DH, Hasiba U, Rabin BS (1978) Asymptomatic structural liver disease in hemophilia. N Engl J Med 298: 1373–1378

    PubMed  Google Scholar 

  23. Steinberg SC, Alter HJ, Leventhal BG (1975) The risk of hepatitis transmission to family contacts of leukemia patients. J Pediatr 87: 753–756

    PubMed  Google Scholar 

  24. Stewart GL, Parkman PD, Hopps HE, Douglas RD, Hamilton JP, Meyer Jr HM (1967) Rubella-virus hemagglutination inhibition test. N Engl J Med 276: 554–557

    PubMed  Google Scholar 

  25. Sutnick AI, Levine PH, London WTh, Blumberg BS (1971) Frequency of Australia antigen in patients with leukaemia in different countries. Lancet I: 1200–1202

    Google Scholar 

  26. Tabor E, Gerety RJ, Mott M, Wilbur J (1978) Prevalence of hepatitis B in a high-risk setting: A serologic study of patients and staff in a pediatric oncology unit. Pediatrics 61: 711–715

    PubMed  Google Scholar 

  27. Theml H, Pralle H, Bartels H, Common H, Gunzer U, Huhn D, Leopold H, Meusers P, Nowicki L, Scholle H, Waldner R, Weissenfels I (Kieler Lymphomgruppe) (1979) Offene Fragen zur Differentialdiagnose, Klinik und Therapie der chronisch lymphatischen Leukämie. In: Lymphknotentumoren. Urban & Schwarzenberg, München, Wien, Baltimore, S 201–206

    Google Scholar 

  28. Wands JR, Walker JA, Davis ThT, Waterbury LA, Owens AH, Carpenter CCJ (1974) Hepatitis B in an oncology unit. N Engl J Med 291: 1371–1375

    PubMed  Google Scholar 

  29. Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105–112

    PubMed  Google Scholar 

  30. Weitzman SA, Aisenberg AC, Siber GR, Smith DH (1977) Impaired humoral immunity in treated Hodgkin's disease. N Engl J Med 297: 245–248 (1977)

    PubMed  Google Scholar 

  31. Young RC, Corder MP, Haynes HA, DeVita VT (1972) Delayed hypersensitivity in Hodgkin's disease. Am J Med 52: 63–72

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. V. Medizinische Abteilung des Städtischen Krankenhauses München-Schwabing, D-8000, München, Bundesrepublik Deutschland

    T. Sauerbruch & H. Kaess

  2. Max von Pettenkofer-Institut der Universität München, D-8000, München

    G. Frösner

  3. I. Medizinische Abteilung des Städtischen Krankenhauses München-Schwabing, D-8000, München

    H. Theml & K. Eggert

Authors
  1. T. Sauerbruch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Frösner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Theml
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Eggert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Kaess
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sauerbruch, T., Frösner, G., Theml, H. et al. Hepatitis B-Virus-Marker und Rötelnantikörper bei Patienten mit Hodgkin-, Non-Hodgkin-Lymphomen und allgemein internistischen Erkrankungen. Blut 40, 259–266 (1980). https://doi.org/10.1007/BF01080185

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01080185

Key words

Schlüsselwörter

Search

Navigation